The DOI matches its Crossref record.
Surrogate Endpoints And FDA’s Accelerated Approval Process
Abstract
There is interest in approaches allowing more rapid availability of new interventions, particularly for diseases providing risks of death or serious illness. The accelerated-approval regulatory process is intended to address this need by allowing marketing of interventions shown to have strong effects on measures of biological activity, if those measures are potential "surrogates" for true measures of tangible clinical benefit. To use surrogate endpoints and the accelerated-approval process, challenging issues must be addressed to avoid compromising what is truly in the best interest of public health: the reliable as well as timely evaluation of an intervention's safety and efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv317 · Cited by 6,931
Contribution of Primary Care to Health Systems and Health
STARFIELD, B., SHI, L., & MACINKO, J. (2005) · The Milbank Quarterly · doi:10.1111/j.1468-0009.2005.00409.x · Cited by 5,507
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2015) · European Respiratory Journal · doi:10.1183/13993003.01032-2015 · Cited by 3,172
The clinical use of structural MRI in Alzheimer disease
Frisoni, G. B., Fox, N. C., Jack, C. R., Scheltens, P., & Thompson, P. M. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.215 · Cited by 2,113
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
Symmans, W. F., Peintinger, F., Hatzis, C., Rajan, R., Kuerer, H., Valero, V., Assad, L., Poniecka, A., Hennessy, B., Green, M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.6823 · Cited by 1,654
Risk stratification and medical therapy of pulmonary arterial hypertension
Galiè, N., Channick, R. N., Frantz, R. P., Grünig, E., Jing, Z. C., Moiseeva, O., Preston, I. R., Pulido, T., Safdar, Z., Tamura, Y., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.01889-2018 · Cited by 819
Updated Treatment Algorithm of Pulmonary Arterial Hypertension
Galiè, N., Corris, P. A., Frost, A., Girgis, R. E., Granton, J., Jing, Z. C., Klepetko, W., McGoon, M. D., McLaughlin, V. V., Preston, I. R., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.031 · Cited by 667
Biomarkers and surrogate endpoints in clinical trials
Fleming, T. R., & Powers, J. H. (2012) · Statistics in Medicine · doi:10.1002/sim.5403 · Cited by 544
Self-citationLammers, W. J., van Buuren, H. R., Hirschfield, G. M., Janssen, H. L. A., Invernizzi, P., Mason, A. L., Ponsioen, C. Y., Floreani, A., Corpechot, C., Mayo, M. J., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.08.029 · Cited by 498
Pharmaceuticalization of Society in Context: Theoretical, Empirical and Health Dimensions
Abraham, J. (2010) · Sociology · doi:10.1177/0038038510369368 · Cited by 480
Dulai, P. S., Sirlin, C. B., & Loomba, R. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.06.005 · Cited by 356
Parker, C., Waters, R., Leighton, C., Hancock, J., Sutton, R., Moorman, A. V., Ancliff, P., Morgan, M., Masurekar, A., Goulden, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)62002-8 · Cited by 330
Do Firms Underinvest in Long-Term Research? Evidence from Cancer Clinical Trials
Budish, E., Roin, B. N., & Williams, H. (2015) · American Economic Review · doi:10.1257/aer.20131176 · Cited by 302
Endpoints for Assessing Drug Activity in Clinical Trials
Pazdur, R. (2008) · The Oncologist · doi:10.1634/theoncologist.13-s2-19 · Cited by 286
Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease
(2010) · National Academies Press eBooks · doi:10.17226/12869 · Cited by 276
Junge, W., Mellinger, U., Parke, S., & Serrani, M. (2011) · Clinical Drug Investigation · doi:10.2165/11590220-000000000-00000 · Cited by 107
The use of intermediate endpoints in the design of type 1 diabetes prevention trials
the Type 1 Diabetes TrialNet Study Group, & Krischer, J. P. (2013) · Diabetologia · doi:10.1007/s00125-013-2960-7 · Cited by 64
Kulkarni, P. S., Hurwitz, J. L., Simões, E. A. F., & Piedra, P. A. (2018) · Viral Immunology · doi:10.1089/vim.2017.0147 · Cited by 53
Metadata
- Authors
- Fleming, T. R.
- Venue
- Health Affairs
- Publisher
- Health Affairs Publishing, LLC
- Published
- 2005-01
- Volume
- 24
- Issue
- 1
- Pages
- 67-78
- ISSN
- 0278-2715 (ISSN-L)
- 1544-5208
- OpenAlex
- W2120368275
- Cited by
- 249
- References
- 0
- FWCI
- 10.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.